Impact Biomedical (IBO) executive compensation, 2025 proxy

Frank D. Heuszel, Chief Executive Officer, was paid $54,806 in 2024.

Open IBO in Gloom →
Impact Biomedical's chart, financials and news, free in your browser.Open IBO in Gloom →
Filed
September 22, 2025
Annual meeting
November 5, 2025
Pay year
2024
Named executives
3
CEO total pay
$54,8062024
CEO pay in equity
20%$11,100 in awards
CEO first-year salary
$200,000Employment agreement
CEO first-year bonus
$150,000Mandatory bonus
Options granted in 2024
880,000$3.00 purchase price
Option fair value
approximately $50,000Black-Scholes valuation
Stock compensation expense
approximately $19,0002024 expense

How Heuszel was paid

$54,806 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary80%Stock awards20%

Named executive officers

ExecutiveTotal
Frank D. HeuszelChief Executive Officer$54,806
Mark SuseckChief Operating Officer$158,689
Todd D. MackoChief Financial Officer$555

What changed and why

  • $54,806$54,806 was Frank D. Heuszel's total compensation for 2024; his 2023 total was shown as a dash.
  • $159K$158,689 was Mark Suseck's total compensation for 2024, including $126,689 salary and $32,000 stock awards.
  • $555$555 was Todd D. Macko's total compensation for 2024, entirely from stock awards.
  • $200K$200,000 was the CEO's contractual base salary for the first year of his October 2024 employment term.
  • $150K$150,000 was the CEO's mandatory bonus specified for the first year of his employment term.
  • $3.00880,000 options were granted during 2024 at a purchase price of $3.00 per share.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.